Galantamine Attenuates Autoinflammation in a Mouse Model of Familial Mediterranean Fever

Overview

Journal Mol Med

Publisher Biomed Central

Specialties General Medicine
Molecular Biology

Date 2022 Dec 9

PMID 36494621

Authors

Ibrahim T Mughrabi

Mahendar Ochani

Mirza Tanovic

Ping Wang

Betty Diamond

Barbara Sherry

Valentin A Pavlov

Seza Ozen

Daniel L Kastner

Jae Jin Chae

Yousef Al-Abed

Affiliations

Soon will be listed here.

Abstract

Background: Autoinflammatory diseases, a diverse group of inherited conditions characterized by excessive innate immune activation, have limited therapeutic options. Neuroimmune circuits of the inflammatory reflex control innate immune overactivation and can be stimulated to treat disease using the acetylcholinesterase inhibitor galantamine.

Methods: We tested the efficacy of galantamine in a rodent model of the prototypical autoinflammatory disease familial Mediterranean fever (FMF). Multiple chronic disease markers were evaluated in animals that received long-term galantamine treatment compared to vehicle.

Results: Long-term treatment with galantamine attenuated the associated splenomegaly and anemia which are characteristic features of this disease. Further, treatment reduced inflammatory cell infiltration into affected organs and a subcutaneous air pouch.

Conclusions: These findings suggest that galantamine attenuates chronic inflammation in this mouse model of FMF. Further research is warranted to explore the therapeutic potential of galantamine in FMF and other autoinflammatory diseases.

References

Rosas-Ballina M, Ochani M, Parrish W, Ochani K, Harris Y, Huston J . Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A. 2008; 105(31):11008-13. PMC: 2504833. DOI: 10.1073/pnas.0803237105. View

Romano M, Faggioni R, Sironi M, Sacco S, Echtenacher B, Di Santo E . Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor. Mediators Inflamm. 1997; 6(1):32-8. PMC: 2365839. DOI: 10.1080/09629359791901. View

Consolim-Colombo F, Sangaleti C, Costa F, Morais T, Lopes H, Motta J . Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial. JCI Insight. 2017; 2(14). PMC: 5518569. DOI: 10.1172/jci.insight.93340. View

Ali M, El-Abhar H, Kamel M, Attia A . Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug. PLoS One. 2015; 10(8):e0134648. PMC: 4532414. DOI: 10.1371/journal.pone.0134648. View

Sapronov N, Nezhinskaya G, Vladykin A . Effects of cholinergic agonists and antagonists under conditions of spleen denervation in rats with endotoxic shock. Bull Exp Biol Med. 2010; 149(5):598-600. DOI: 10.1007/s10517-010-1002-4. View

Ben-Chetrit E, Levy M . Familial Mediterranean fever. Lancet. 1998; 351(9103):659-64. DOI: 10.1016/S0140-6736(97)09408-7. View

Ben-Zvi I, Livneh A . Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol. 2010; 7(2):105-12. DOI: 10.1038/nrrheum.2010.181. View

Masters S, Simon A, Aksentijevich I, Kastner D . Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009; 27:621-68. PMC: 2996236. DOI: 10.1146/annurev.immunol.25.022106.141627. View

Sharma D, Sharma B, Vogel P, Kanneganti T . IL-1β and Caspase-1 Drive Autoinflammatory Disease Independently of IL-1α or Caspase-8 in a Mouse Model of Familial Mediterranean Fever. Am J Pathol. 2016; 187(2):236-244. PMC: 5389372. DOI: 10.1016/j.ajpath.2016.10.015. View

10.

Alpa M, Roccatello D . Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015; 9:1983-7. PMC: 4408939. DOI: 10.2147/DDDT.S69117. View

11.

Chhatar S, Lal G . Role of adrenergic receptor signalling in neuroimmune communication. Curr Res Immunol. 2022; 2:202-217. PMC: 9040148. DOI: 10.1016/j.crimmu.2021.11.001. View

12.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S . The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011; 1813(5):878-88. DOI: 10.1016/j.bbamcr.2011.01.034. View

13.

McKinley M, Martelli D, Trevizan-Bau P, McAllen R . Divergent splanchnic sympathetic efferent nerve pathways regulate interleukin-10 and tumour necrosis factor-α responses to endotoxaemia. J Physiol. 2022; 600(20):4521-4536. DOI: 10.1113/JP283217. View

14.

Akiyama T, Yamazaki T, Mori H, Sunagawa K . Inhibition of cholinesterase elicits muscarinic receptor-mediated synaptic transmission in the rat adrenal medulla. Auton Neurosci. 2003; 107(2):65-73. DOI: 10.1016/S1566-0702(03)00129-2. View

15.

Sramek J, Frackiewicz E, Cutler N . Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs. 2000; 9(10):2393-402. DOI: 10.1517/13543784.9.10.2393. View

16.

Kanneganti A, Malireddi R, Saavedra P, Vande Walle L, Van Gorp H, Kambara H . GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. J Exp Med. 2018; 215(6):1519-1529. PMC: 5987922. DOI: 10.1084/jem.20172060. View

17.

Chomarat P, Banchereau J, Davoust J, Palucka A . IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2001; 1(6):510-4. DOI: 10.1038/82763. View

18.

Shifrin H, Nadler-Milbauer M, Shoham S, Weinstock M . Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013; 8(2):e57668. PMC: 3585220. DOI: 10.1371/journal.pone.0057668. View

19.

Murray K, Rude K, Sladek J, Reardon C . Divergence of neuroimmune circuits activated by afferent and efferent vagal nerve stimulation in the regulation of inflammation. J Physiol. 2021; 599(7):2075-2084. PMC: 8016722. DOI: 10.1113/JP281189. View

20.

Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U . Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007; 119(2):e474-83. DOI: 10.1542/peds.2006-1434. View